Cancer Research Institute (CRI) shared on LinkedIn:
“From NK cell therapies to AI-driven advances, SITC26 spotlighted the future of cancer immunotherapy.
Our recap highlights:
- The CRI William B. Coley Award Lecture: Eric Vivier, DVM, PhD, on harnessing NK cells in cancer therapy.
- Fireside conversation: Dr. Vivier and CRI STAR Yvonne Chen, PhD, discuss the future of cell therapy and AI.
- CRI poster presentation: A global analysis of 929 checkpoint bispecific antibody trials examining innovation in the field.
The Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting (SITC 2026) took place on November 4–8, 2026, in Phoenix, Arizona, bringing together researchers, clinicians, and other experts in cancer immunotherapy. The meeting focused on a central question: how to help more patients benefit from cancer immunotherapy.
The scientific programme explored advances in understanding how immune cells recognize and target cancer, developing innovative immunotherapies, and improving research tools and technologies. Through scientific presentations, expert discussions, and collaboration, the meeting highlighted ongoing efforts to advance cancer immunotherapy and expand its benefits to patients.
Other posts about SITC26 on OncoDaily.
